This suggests that the mechanism of action of triclabendazole is not specific to the MPSPS mutation but rather directly affects the intrinsic GAG metabolic system, and that triclabendazole may apply to a wider range of mucopolysaccharide accumulation diseases, such as mucopolysaccharidoses and mucolipidoses. Here, VPS33A is linked to mucopolysaccharidosis.